Point72 Asset Management
PTLA

Point72 Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Point72 Asset Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-431,200
Closed -$8.8M – 929
2016
Q1 		$8.8M Buy
+431,200
New +$13.7M 0.07% 312
2014
Q4 		– Sell
-160,000
Closed -$4.04M – 834
2014
Q3 		$4.04M Buy
+160,000
New +$4.21M 0.03% 426

Other funds holding PTLA

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Point72 Asset Management's PTLA Position: Q2 2016 in Review

Point72 Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2016, closing a stake of 431,200 shares — an estimated $8.8M sold.

Point72 Asset Management first reported a position in PTLA in Q3 2014 and held it in 2 quarters. The position peaked at $8.8M in Q1 2016. 159 funds tracked by Wall St. Rank hold PTLA as of Q2 2016.

  • Point72 Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Point72 Asset Management sold 431,200 Portola Pharmaceuticals, Inc. shares in Q2 2016, an estimated $8.8M.
  • Point72 Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2014 and held it in 2 quarters.
  • Point72 Asset Management's Portola Pharmaceuticals, Inc. position peaked at $8.8M in Q1 2016.
  • 159 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2016.

Based on Point72 Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.